Assembly Biosciences
Alex Thompson is Professor-Director of the Department of Gastroenterology at St. Vincent’s Hospital and the University of Melbourne, Australia, NHMRC Practitioner Fellow and Adjunct Assistant Professor of the Department of Gastroenterology, Duke University Medical Center. Professor Thompson is the Clinical Lead for the statewide hepatitis program in Victorian Prisons, contracted to the Victorian Government’s Department of Justice and Community Safety, and a past President of the Australian Liver Association. His research focusses on improving outcomes for people living with viral hepatitis. He was involved in the discovery of IL28B polymorphism as a predictor of treatment outcome in HCV and is an active clinical investigator for trials evaluating the efficacy of novel antiviral DAA regimens. With the development of DAA therapy for HCV, he has more recently been actively pursuing the development and evaluation of new models of care for people with HCV, with a focus on prisoners and treatment as prevention to eliminate transmission and reduce prevalence of HCV in Australia. He has published widely in journals including Nature, New England Journal of Medicine, Journal of the American Medical Association, Gastroenterology, Hepatology, Gut and Journal of Hepatology.
This person is not in the org chart
This person is not in any offices
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.